Evidence map›Paper›PMID 17204482›Full record

ArticleThe Journal of biological chemistry2007

Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells.

Shizhen Emily Wang, Archana Narasanna, Corbin W Whitell, Frederick Y Wu, David B Friedman, Carlos L Arteaga

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Murine microenvironment metaprofiles associate with human cancer etiology and intrinsic subtypes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013
    Article
  11. Article
  12. Article
  13. TGF-β mediated DNA methylation in prostate cancer.Translational andrology and urology · 2012
    Article
  14. Article
  15. When tumor suppressor TGFβ meets the HER2 (ERBB2) oncogene.Journal of mammary gland biology and neoplasia · 2011
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shizhen Emily WangDepartment of Cancer Biology, Mass Spectrometry Research Center, Breast Cancer Research Program, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.
Archana Narasanna
Corbin W Whitell
Frederick Y Wu
David B Friedman
Carlos L Arteaga
Vanderbilt University · USBreast Cancer Research Foundation · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
TISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7M
ERBB2 TARGETED ANTITUMOR STRATEGIES IN BREAST CANCERR01CA080195 · NCI · VANDERBILT UNIVERSITY · PI ARTEAGA, CARLOS L · 1999 to 2014
$3.9M
TGF-BETAS AND RECEPTORS AND HUMAN BREAST CELLSR01CA062212 · NCI · VANDERBILT UNIVERSITY · PI ARTEAGA, CARLOS L · 1995 to 2009
$2.9M
Crosstalk TGFbeta and HER2 (ErbB2) Signaling in Mammary TumorigenesisR00CA125892 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI WANG, SHIZHEN EMILY · 2009 to 2011
$906k
Crosstalk TGFbeta and HER2 (ErbB2) Signaling in Mammary TumorigenesisK99CA125892 · NCI · VANDERBILT UNIVERSITY · PI WANG, SHIZHEN EMILY · 2007 to 2008
$238k
NCI NIH HHS K99 CA125892NCI NIH HHS P30 CA068485NCI NIH HHS P30 CA68485NCI NIH HHS P50 CA098131NCI NIH HHS P50 CA98131NCI NIH HHS R00 CA125892NCI NIH HHS R01 CA062212NCI NIH HHS R01 CA080195NCI NIH HHS R01CA62212NCI NIH HHS R01CA80195
6 · The paper itself

Abstract

Using two-dimensional difference gel electrophoresis, we identified the tumor suppressor gene maspin as a transforming growth factor beta (TGFbeta) target gene in human mammary epithelial cells. TGFbeta up-regulatesMaspin expression both at the RNA and protein levels. This up-regulation required Smad2/3 function and intact p53-binding elements in the Maspin promoter. DNA affinity immunoblot and chromatin immunoprecipitation revealed the presence of both Smads and p53 at the Maspin promoter in TGFbeta-treated cells, suggesting that both transcription factors cooperate to induce Maspin transcription. TGFbeta did not activate Maspin-luciferase reporter in p53-mutant MDA-MB-231 breast cancer cells, which exhibit methylation of the endogenous Maspin promoter. Expression of ectopic p53, however, restored ligand-induced association of Smad2/3 with a transfected Maspin promoter. Stable transfection of Maspin inhibited basal and TGFbeta-stimulated MDA-MB-231 cell motility. Finally, knockdown of endogenous Maspin in p53 wild-type MCF10A/HER2 cells enhanced basal and TGFbeta-stimulated motility. Taken together, these data support cooperation between the p53 and TGFbeta tumor suppressor pathways in the induction of Maspin expression, thus leading to inhibition of cell migration.

Indexed as

Cell Line, TumorCell MovementEpithelial CellsGenes, Tumor SuppressorHumansMammary Glands, HumanPromoter Regions, GeneticSerpinsSignal TransductionSmad2 ProteinSmad3 ProteinTranscriptional ActivationTransforming Growth Factor betaTumor Suppressor Protein p53Up-RegulationSERPIN-B5SerpinsSmad2 ProteinSMAD2 protein, humanSmad3 ProteinSMAD3 protein, humanTransforming Growth Factor betaTumor Suppressor Protein p53

Identifiers

PMID17204482
PMCPMC4015524
OpenAlexW2153767510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.